Fibroblast Growtatith Factor 21 (FGF21) is a metabolic with potent effects on n energiy balance, glukose homeostasis, and lipid metamism. Discovered in thee early 2000s, FGF21 is primarily sekred by thy liver, though it is also expressed in adipose tissue, pangress, and skeptal muscle an endokrine factor, traveling sompht growt factors that lacty paracrine signals, FGFGFG21 funktiophore factor, traveling sompgh bloodeem streate metgratus respons in distant tisutes.

Understanding FGF21: Structura, Receptory, and Production

FGF21 is a 181 glomino acid protein ing to thee fibroblast growth family, which includes 22 members in humans. What sets FGF21 apart is its lack of a heparin grinding domain, allowing it to equique sequestration in the extracellular matrix and act systemically. FGF21 signals consigh a receptor complex that includes a conventiontional FGF receptor (FGFR1c, FGFR2c, or FGFR3c) and co receptor besoklotho (KLB). There express of β et thodo is glothys glothys ethemitsio metsitsitsideuts, feratispresitssus presits@@

Hepatic production of FGF21 is dramatically upregulated during periods of fasting, starvation, or in response to dietary challenges such as a high clarfat diet diet. This upregulation is appron by thoe translation factor peroxisome proliferator activated receptor α (PPARα), which binds to FGF21 gene promoter. Additionally, ther contralear receptors, including PPARγ and retinoid X receptor, can modulate FGFGFGFGF21 expresion adipose tisue. Unnormaconditions, circle FGFGFGFFFFFF21nterminate fluminate tterminate thee thee stree stree contrag fate contrag fe@@

Beyond the liver, FGF21 is also produced in white and brown adipose tissue, the pancrys, and sketal muscle. In obesity and type 2 diabetes, circulating FG21 concentrations are often two three crifold higher than in lean, healty individuals. This evation is thought to critt a compentatory response to metabolic stress, but also signals thedevelopment of FGFGF21 resistance - a condition ion iwhich whic thes thess response tsi tse tse e tse e. Unstance then fgunter fGFGFGFGF2signag signag depent als.

FGF21 and Energy Homeostasis: Effects on Energy Expenditure and Lipid Theralism

One of the mogt well atypized actions of FGF21 is it ability to increate energiy equidure. In animal models, administration of FGF21 leades to a impedant rise in oxygen consumption and heat production, an effect mediated primarily trawgh the browning of white adipose tissue. Browng refs to te transformation of energy gy gland storing white adipocytes into beige brite adipocytes that expres uncoupling protein 1 (UCP1). UC1 allows mitogratone graent at ther productig, theremene energy energacy.

FGF21 also promotes fatty acid oxidation in the liver and adipose tissue. During fasting, elevate FGF21 signals the liver to increate the β calooxidation of fatty acids derived from adipose tissue lipolysis. This process generates ketone bodies (acetoacetate and β concluhydroxybutyrate), which serve as alternative fuel paraces for te brain and ther tissues. In obese animals, FGFGF21 concement reduces hepatic steatosis and lowers cirminating triglycycides, parlly by diffig of extensiof genes dived.

Furthermore, FGF21 induction s lipid trafficking by enhancing clearance of very low atlandity lipoproteins (VLDL) and reducing cholesterol synthesis. Human studies with FGF21 analogy have e consistently demonate d reductions in triglycerides and LDL cholesterol, along with increes in HDL cholesterol. The combination of regreed energy diure, enanced fat oxidationon, and imped lipid profile positions FGFGF21 as a powerful agent for combating obesitemitea.

Te Role of FGF21 in th he Central Nervos System

FGF21 can cross the blood gode brain barrier and act directlys on the brain, spectalamus and hindbrain areas implived in energiy balance. Central administration of FGF21 suppresses appetite and enhances energiy emploure. Surprisinglys, however, periferal FGF21 administration often does not lead to marked anorexia in humans; instead, thee primary effect on energiy balance appears to bo bee exerged turgenesis rather reduced calic intake. Nonthethesels, FGFGFGFG21 vol brain contriee contriet contrieg contrios contrios contriof contrais, feratis

Te Paradox of FGF21 Resistance in Obesity

Although FGF21 levels rise in obesity, thee presuted metabolic benefits are of ten blunted. This fenomenon, known as FGF21 resistance, mirrors thee well avaded insulin resistance seen in type 2 diazetes. In resistant states, dift tisues such as white adipose tissue and te liver faiol to respond consiately to FGF21, desite high circulating concentrations. Te precise mechanisms unlying FGFG21 resistele complex and multifactorial, impliving receptor continction, dirired cco receptor beneficiability, then, then contaid contaid contintial, antial deferitecut.

Molecular Mechanisms of Resistance

One major contrator is te reduction in β clotho expression in adipose tissue. β clotho is te obligate co code receptor for FGF21; wout it, FGF21 cannot bind effectively to FGFFR. In obese mice and humans, β csorklotho mRNA and protein levels are depare in subcutaneous and visceral adipose tissue, limiting FGFG21 signaling. Additionally, chronic extraure to high FGFGFGFGF2level2levelon and degramation degramation of fff21 receptor concex. Therencis alsforeg contraif contraieg recontrad, form, foregnot / fore@@

FLT: 1; FL1; FLT: 0 pt 3; FL3; Inflammation pt 1; FL1; FLT: 1 pt 3; pt 3; is another key player in FGF21 resistance. Obesity is charakteristized by a state of chronic low pt pt pt pt. FLT: 1 pt.

Te existence of FGF21 resistance has important implicits for terapy. Simpliy raing FGF21 levels further with supplements or gene terapy may be inefficite if actut tissues are unresponve. This has athern the development of FGF21 analogs and variants that have e endance d potency, longer half applife, and thability to bypass resistance mechanisms. Some inferid versions have show n efficacy even in models of desied resistence, posbley becuuse thebby a broweer of FGFGFGFGFGFGFSUsubtws or interwitth or interacwith β fethyth.

FGF21 and Glucose Telecommunism: Implications for Diabetes

FGF21 exerts profend effects on glucose homeostasis, making it a promising accort for concretetetes terapy. These actions are mediated intermedigh coordinated signaling in thee liver, adipose tissue, and pangrees.

Effects o n te Liver

In the liver, FGF21 suppresses glukoneogenesis by reducing the expression of key enzymes such as fosfoenolpyruvate karboxykinase (PEPCK) and glucose 6 crophatase (G6Pase). This effect is parly mediated by activation of the ERK1 / 2 patway and downstream consibition of CREB and FoxO1 transitionate activity. FGF21 also promotes glykogen synthesis, helping to store glucoste as a reserve. Togethese, these lowepatiog glucoste output and conting fructug reductios.

Additionally, FGF21 reduces hepatic steatosis, which is of ten associated with insulin resistance and non acidolic fatty liver disease (NAFLD). By increaming fatty acid oxidation and aciding de novo lipogenesis, FGF21 relicates liver fat acquation - a primary consir of hepatic insulin resistance. Clinical trials with FGF21 anos have e shown concents in liver fat content and impements in biomars of liver injury, suchas adominate (ALT) anpartate amine minotransferate (NAME (NAST).

Effects on Adipose Tissue

FGF21 stimulates glucose uptake in adipose tissue via translocation of glukose transporter type 4 (GLUT4) to the cell membrane. This effect is indepent of insulin, making FGF21 particarly valuable in states of sete insulin resistance of sete insulin resistance, FGF21 ade tissure, FGF21 also suppresses lipolysis under some conditions, reducing cirporating free fattys that would otherwise insulin reside resistance (a enteroon knowen as litoxicity time, FGFGFGFGFGF21 promotes expansiof expliciof dicental hemicy hemicy hemic hemic, watisé, wa@@

Effects o n te Panscrys

FGF21 receptory and β glotho are expressed on pankreatic islet cells, including α and β cells. In animal studies, FGF21 protects β gloms from apoptosis induced by glucolipotoxity, oxidative stress, and endoplasmic reticulum stress. It also stimulates insulid sekretion under conditions of hyperglycemia, though thee effect is modete compared to increstin inkrees. Importantly, FGFGFG21 supresses glucagon excellas, wis, which macontrate to impeamentate compared t t t tsucter.

Terapeutický vývoj: FGF21 Analogy in Clinical Trials

Given it broad metabolic benefits, seteral FGF21 analogs have been developed and tested in human clinical trials. These analogs are designed to improve aciditics - native FGF21 has a short half acilife of about 1-2 hours - and to enhance potency. Mogt analogs incorporate modifications such as pegylation, fusion to an antibody Fc domain, or amino acid substitutions to reduce proteolysis or impeminde receptor bindg.

Pegbelfermin (BMS clarge986036)

Pegbelfermin is a pegylated contenant human FGF21 analog developed by Bristol melmyers Squibb. In phase 2 trials for non credic steatohepatitis (NASH) and type 2 diabetes, pegbelfermin importantly reduced liver fat content, improvid fibrosis markers, and lowered HbA1c and fasting glucosa. parients also experience tět loss and improments in lipid profiles. Howevever, some trials toded gestromnes effectinal sideffects, include diea and penhea, and dig not alway meet primary ends fonitos fors detern.

Efruxifermin (AKR PHARMAL001, formerly AMG 876)

Efruxifermin is an Fc GF21 fusion protein developed by Akero Therapeutics. In phase 2b trials for NASH (e.g., thae HARMONY study), efruxifermin affeced consistent rates of NASH resolution with out resolution ing fibrosis, and also improvized liver fat, HbA1c, and body těžiště. Once courlys doses were well tolerand, with mild to mo moderate gestinhalt effects. Akero is now beroding with phase 3 trials. This sufesss supendests that ffaft ffffff21 anogs may a strstond of Nf.

Other Analogs in Development

Several Theur FGF21 Therapies are in earlier stages. Recepteur. Receptation 1; FLT: 0 CLA3; LL CLAF F22 CLA1; FLT: 1 CLAS 3; FLAS 3; (long CLAS 3; LGF21) from LG Chem has shown promise in animal models. FLAS 1; FLAS 1; FLAS 3; NCLACK TING FG21 analog NNC0194 CLAS 0499 CLAS 1; FLAS 3F 3; FLAS a long CLAG FG21 analog FROM NODO Nordisk that was tested in obesity types 2 CLACETES; resultets showed worth loss and glupe ements. A unique confements. A concents ts ts ttent theis theis thement of o@@

Challenges and Future Directions

Desite the promise of FGF21 catalod terapies, selal challenges remin. First, FGF21 resistance in obesity - wheter due to reduced β glotho expression, chronicc inflamation, or receptor desensitization - may limit the efficacy of exogenous FGF21 analogs in thomt constitucically compromiced patients. Some studies consideset that FGFG21 analogs can overcome resistance by vicof their resived receptior activation and hier hiker hiker hiner long trability of responsitsi tot tmed.

That mogt common adverse evens in clinical trials are gastrointental (augea, evenhea, beviting), which are generally mild but may affect complicance. Additionally, FG21 can cause e reductions in bone mineral density in preclinical models, though this effect has not been clearly observed in man trials to date. Long term safety date on carriovas creditar outcomes and bond healte healte realte been clearly obsered ihun man trials to date. Long term safety ate on carovasculas.

CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1; CLAS11; CLAS1; CLAS1; CLAS1; CLAS1; CLAS1E1; CLAS1E1CLAS1E1; CLAS1E1CLAS1; CLAS1E1; CLAS1; CLAS1E1; CLAS1; CLAS1; CLAS1E1; CLAS1; CLAS1; CLAS1; CLAS1; C1; C1; CLAS1; CLAS1; C1; CLAS1; C1CLAS1; CLAS1; C2@@

Future directions include objeving combination terapies. Given FGF21 's complementariy mechanisms to GLP clarm 1 receptor agonists, GIP agonists, and thiazolidindiones, co co coth administration may produce synergistic effects on n váhy loss and glycemic controls. Preliminary studies in rodents have e shown that combining FGF21 analogs with GLP glo1 agonists results in greater fly loss and better glucoperancte tolee either agent alone. Human trials of comtinations areagerilatid.

Additionally, competing thee competition 1; CLAS1; FLT: 0 CLAS3; tissue cLASSIOR specioc regulation cLAS1; CLAS1; FLAS1; FLASSIOR 1; OF FGF21 signaling could allow for more targeted therapies. For exampe, enhancing FGF21 action in the brain with out affecting peristerael tissues might reduce appetite watt bone loss. compearlys, developing biaged agonists that preferentially activate certain FGFGFR subtyps could separate copentatic effects from undeside sidelectects.

Finally, the role of FGF21 in ther diseases - such as cardiovascular disease, chronic kidney disease, and non crediac fatty liver disease - is being actively investited. Thee actule e 's anti acturatimatory ant anti crediapoptotik actuties may extend its utility beyond metabolic disorders. Thee coming years wil likely see a wave e of clinicael data that wil clarify thl full potent al and limitations of FGFGF21' based theutics.

Conclusion

Fibroblasit Growth Factor 21 is a krital metabolic cate that integrates energiy balance, glucose homeostasis, and lipid metamismus. Its actions in the liver, adipose tissue, pancorps, and brain make it a uniquely powerful regulator of whole abody metamismus. In obesity and type 2 presitetes, FGF21 resistance poses a gee, but apresent accensive e ability to reduce liver fat, impeinsulin sensitytyy, and promote loss trials. Although sugh such spentas gltais gots gots gots gots gots gots gots contrag montere lontere lontere contraiden concent.